CD3-specific antibodies: a portal to the treatment of autoimmunity

Lucienne Chatenoud,Jeffrey A. Bluestone

DOI: https://doi.org/10.1038/nri2134

IF: 108.555

2007-07-20

Nature Reviews Immunology

Abstract:Key PointsThis Review summarizes the results from preclinical and clinical studies that use CD3-specific monoclonal antibody therapy and highlights future combination opportunities to enhance the efficacy of this promising immunotherapeutic.CD3-specific monoclonal antibodies inactivate pathogenic cells by inducing rapid internalization of the T-cell receptor (TCR)–CD3 complex from the cell surface. Upon TCR re-expression and exposure to the autoantigen, an 'altered' TCR signal causes the T cells to die, become anergic or even change from a pathogenic to a regulatory T-cell phenotype.Preclinical studies strongly suggested that the long-term therapeutic effect of CD3-specific monoclonal antibodies in non-obese diabetic (NOD) mice could not be explained solely by their capacity to eliminate and/or inactivate pathogenic T cells. Evidence suggests that this long-term effect results as a consequence of a significant increase in the number of transforming growth factor-β (TGFβ)-dependent adaptive regulatory T cells, as well as an increased sensitivity of pathogenic T cells to the effects of regulatory T cells.At variance with presently available therapies for autoimmunity and transplantation, CD3-specific monoclonal antibodies afford long-term effects following a short administration — a capacity that is directly linked to their tolerogenic properties. The present challenge is to build on this experience; first to attain the use of CD3-specific monoclonal antibodies as an established therapy in well-selected subsets of patients with autoimmune diabetes; second, to adapt CD3-specific monoclonal antibody treatment to other autoimmune disorders in which it could also prove beneficial; and third, to use CD3-specific monoclonal antibody therapies in combination with other treatments for increased efficiency.

immunology